News and Announcements
Analytica’s AutoStart Burette Granted US Patent
- Published July 15, 2016 11:30AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th July 2016, ASX Announcement
Analytica (ASX:ALT) is pleased to announce that the AutoStart® burette system has been granted patent protection by the US Patent and Trademarks Office.
US Patent 9352080 has a priority date of 13 October 2005 and will expire on 17 Jan 2031, provided all renewal fees are paid.
CEO Geoff Daly said “Obtaining patent protection in the world’s largest medical device market is a major milestone and an important step in the commercialisation of the AutoStart infusion System. The patent process is lengthy and complex, with this national phase patent taking more than 10 years from the priority date. This patent is one of a number of AutoStart burette patents being pursued in the major medical device markets.”
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
